Boston Scientific Corporation
44.96USD
-0.0200 (-0.04%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.7B | 14.2B | 16.7B | 20.1B | 21.4B | 22.3B |
| Q1 | 3.0B | 3.4B | 3.9B | 4.7B | 5.2B | — |
| Q2 | 3.2B | 3.6B | 4.1B | 5.1B | 5.4B | — |
| Q3 | 3.2B | 3.5B | 4.2B | 5.1B | 5.3B | — |
| Q4 | 3.2B* | 3.7B* | 4.6B* | 5.3B* | 5.4B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | .450 | 1.07 | 1.25 | 1.94 | 3.30 | 3.43 |
| Q1 | .070 | .210 | .330 | .450 | .900 | — |
| Q2 | .170 | .180 | .220 | .530 | .610 | — |
| Q3 | .120 | .340 | .320 | .510 | .805 | — |
| Q4 | .097* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .344* |
| .378* |
| .448* |
| .837 |
| — |